This marks a significant new indication for cadonilimab beyond gastric, lung, and cervical cancers, and represents the 13th Phase III/registrational study of the therapy conducted globally.
The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...
Pharmaceutical Technology on MSN
Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a ...
The FDA has approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient mismatch repair, ...
Colorectal cancer most often spreads to the liver. When those liver tumors (called liver metastases) can be removed with ...
Genentech, part of Roche Group (USOTC:RHHBY), has received FDA approval for Tecentriq in combination with chemotherapy for a ...
Exercise helped colon cancer survivors live longer in a major trial. But an October 6 report in The New York Times highlights ...
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with ...
Anchor] Recently, colorectal cancer patients in their 20s and 30s have been increasing significantly. Reports indicate that ...
WSW, NY, October 9th, 2026, FinanceWireTwo announcements on the same day put a validated European application and full ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) and Tecentriq Hybreza ® ...
Cancer arrives suddenly one day.That is what I thought.But looking back on my life, cancer has always been close by.Before I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results